Type IV Ehlers-Danlos Syndrome Type IV Ehlers-Danlos Syndrome associated with factor VIII associated with factor VIII deÞ ciency deÞ ciency Sir, A 25-year-old patient was referred to us for itching and scaling over the scalp, face, and chest. The patient was at that time admitted for evacuation of a hematoma following a minimal trauma. The patient was a diagnosed case of factor VIII deficiency, with history of blood/clotting factor transfusions on several occasions. On examination there was minimal scaling and erythema restricted to the scalp, face, and chest. A clinical diagnosis of seborrheic dermatitis was made. Incidentally, on whole body examination, multiple healed scars were noticed on the patient's body. Moreover, the patient had multiple varicosities over both lower limbs [ Figure 1 ] and significant hyper-elasticity of the skin and hyper-mobility of both large and small joints. On taking a detailed history regarding the same, the patient reported easy bruising, delay in wound healing, and excessive gaping of wounds since childhood. The patient mentioned that he was very good at 'break dancing' because his joints were very flexible. There was no known family history of either easy bruising/bleeding disorders or joint hyper-mobility. There was no history of pneumothorax / pneumohemothorax, gastrointestinal involvement, tendon or muscle ruptures.
The patient had been evaluated in various tertiary care centers for the last 15 years for his recurrent bruising tendencies. Except for a marginal low activity of factor VIII and a corresponding mild abnormal aPTT, his coagulation profile was normal. Based on this, he was labeled as a case of factor VIII deficiency and was treated on the lines of the same. His bruising tendency, however, did not show a significant response to the treatment.
On examination we were able to demonstrate marked joint hyper-mobility, especially of the small joints of the hand [ Figure 2] . A positive Gorlin's sign was also elicited [ Figure  3 ]. The patient's skin also had a thin, translucent appearance. Other significant findings included a characteristic facies with thin lips and philtrum, a small chin, and a pinched nose. The patient also had a large hairy melanocytic nevus extending over his right arm and forearm. He also gave a documented history of an arteriovenous malformation adjacent to the site of the melanocytic nevus, which was excised earlier and apparently had taken a long time to heal.
The patient was investigated considering a diagnosis of Ehlers-Danlos syndrome (EDS). The findings from ophthalmic examination were normal. Imaging studies, including MRI and scintigraphy, did not show any other significant hemangiomas / arteriovenous malformation. The patient was referred to the Department of Pediatric Genetics at our institution, where he was taken up for DNA molecular studies, and the specimens were sent to the University of Washington, Seattle, Washington. The DNA analysis demonstrated a mutation (C.1662 + 1G>T IVS24 + 1G>T) in one allele of COL3A1, the gene that encodes pro α 1(III) chains of type III collagen. The mutation results in the skipping of exon 24 and deletion of 18 amino acids in the pro α 1(III) chains encoded by the mutant COL3A1 allele. These molecular findings confirmed the diagnosis of EDS type IV. The findings from other blood investigations were normal except for the abnormal activated partial thromboplastin time (APTT) values (t-41 seconds / c-31 seconds); prothrombin (PT) values were normal, and latest factor VIII activity result was 67.6%. Factor VIII assay was done earlier elsewhere had been persistently low. Virtually all of his symptoms can be explained on the basis of the type IV EDS. The prolonged APTT with a mild factor VIII deficiency, we believe, is just an association, which might have contributed to the severity of the symptoms. Unfortunately for the patient, the diagnosis of EDS was completely missed till the age of 25 years. disorder characterized by joint and dermal manifestations as in other forms of the syndrome, with proneness to spontaneous rupture of bowels and large arteries. The prevalence for all forms of EDS varies between 1/10,000 and 1/25,000, the EDS type IV representing approximately 5% to 10% of cases. The vascular complications may affect all anatomical areas, with a tendency for affecting arteries having large and medium diameter. [1] Superti-Furga et al. [2] provided the first description of a mutation in the COL3A1 gene in type IV EDS. Since then, many different types of mutations in the COL3A1 gene in EDS IV have been reported. It has also been known for a long time that different mutations affecting the stability and secretion of the pro alpha 1(III) chains of type III procollagen can be involved in EDS, suggesting that EDS type IV is biochemically heterogeneous. [3] Molecular analysis is essential for confirmation of EDS IV, even though a diagnosis can be made essentially on a clinical basis.
EDS IV or the vascular type of EDS is an autosomal dominant
There have been many reports of EDS associated with bleeding tendencies. This includes clotting factor deficiencies, VonWillebrand's disease, and platelet dysfunctions. [4] [5] [6] The exact basis for such an association is still not clear though.
One of the points we would like to highlight through this case is the need to look for associated coagulation defects in cases of EDS. Though EDS is known to be associated with bruising, an underlying coagulation defect may accentuate the bruising tendency. In our case, interestingly, the coagulation defect, which we believe is only an incidental minor association, was identified early but unfortunately the EDS went undiagnosed for so long. Vascular EDS alone would explain the history of recurrent bruising and hematomas in the patient. Moreover, the factor VIII levels were always only marginally low, which could not explain the severity of his symptoms. Another interesting incidental association in our case was a larger hairy melanocytic nevus over the right upper limb. To the best of our knowledge this is the first case of type IV EDS, confirmed by molecular analysis, reported in Indian literature.
Persistent atypical varicella in Persistent atypical varicella in two renal transplant patients and two renal transplant patients and its relation to mycophenolic acid its relation to mycophenolic acid Sir, Mycophenolic acid (MPA) is a recently introduced immunosuppressant for the prevention of graft rejection after various solid organ transplantations. It has significantly decreased the incidence of graft rejection due to its augmented immunosuppressive potential. However, this feature might have led to increased chances of various infections. [1, 2] Though there are a few reports revealing increased incidence of varicella zoster virus (VZV) infections in patients following the use of mycophenolate mofetil (MMF), [1, 2] none have described the altered cutaneous manifestations and the course of varicella as was seen in our patients.
The first patient was a 24-year-old man who underwent renal allograft transplantation following chronic renal failure and was started on oral tacrolimus (12 mg/d), MPA (1.44 g/d), and prednisolone (17.5 mg/d). On the 36 th day post-transplant, he developed papules, vesicles, pustules with central necrosis and crust formation all over the body, associated with highgrade fever. At places, lesions were subsiding with pocklike scars. There was neither previous history of varicella in the patient nor of any contact with VZV or herpes simplex virus (HSV). Pre-surgery or post-eruption, VZV or HSV serology could not be done. Tzanck smear from the vesicle showed giant cells, as well as acantholytic cells. There was no mucosal involvement. Liver enzymes, complete blood cell counts, chest X-ray, and electrocardiograph (ECG) were within normal limits. Serum creatinine level was maintained at the baseline level.
The patient was hospitalized because of high-grade fever and was started on oral valacyclovir, 1 g thrice a day. After 1 week of treatment, he became afebrile, and all the vesicular lesions subsided. While the patient was on the same medications, numerous erythematous well-defined papules and plaques studded with multiple tiny necrotic areas having spiny feel appeared on the sites of subsided vesicles over the face, limbs, and upper back [ Figure 1 ]. Skin biopsy from one of these lesions was nonspecific. He was advised to continue oral valacyclovir in the same dose. Even after 2 weeks of antiviral therapy, none of these papulo-plaque lesions subsided, though no new vesicular lesion appeared. With the suspicion that continuation of MPA could have resulted in the persistence of lesions, mycophenolate was withheld altogether and valacyclovir was continued; tacrolimus dose was adjusted to 10 mg/d. Subsequently, the skin lesions started clearing. At the end of the fourth week of the onset of skin lesions, the patient developed posterior outer retinal necrosis, a known systemic complication of varicella. Valacyclovir was stopped and he was started on intravitreal and intravenous ganciclovir, which was continued for 2 months. Following this treatment, all the skin lesions subsided within 2 weeks, leaving post-inflammatory hyperpigmentation and scarring. The patient maintained a stable graft function throughout the course of the illness. There was no evidence of clinical relapse of varicella after 12 months of follow-up, while the patient continued to take oral tacrolimus and prednisolone. MPA was not restarted later.
The second patient was a 28-year-old man, was a known case of hypertensive benign nephrosclerosis resulting in chronic renal failure, who underwent renal allograft transplantation The evolution and morphology of the lesions were similar to those in the previous patient [ Figure 2 ]. Even after 2 weeks of antiviral therapy, hardly any of the papulo-plaque lesions cleared, though there was no new vesicle formation or clinical sign suggestive of dissemination of infection. MPA was withheld altogether as in the previous patient, and doses of tacrolimus (8 mg/d) and prednisone (10 mg/d) were reduced. Following 4 weeks of oral valacyclovir use, the patient became lesion free. MPA was not restarted, as in the previous patient.
